EpimAb Biotherapeutics, a Shanghai, China-based biopharmaceutical company specializing in bispecific antibodies, closed a $25m Series A funding.
The round was led by Oriza Seed Capital with participation from Decheng Capital, 3E Bioventures Capital and the Trend Investment Group.
The company intends to use the funds to advance its proprietary bispecific platform technology and build a pipeline of therapeutic candidates in immuno-oncology and other areas. The start of the first clinical trial with a proprietary program is anticipated for 2018.
In conjunction with the funding, Dr. Ning Li from Oriza and Dr. Min Cui from Decheng will both join the Board of EpimAb.
Founded in 2015 by Chengbin Wu, PhD, CEO, Epimab Biotherapeutics has developed a novel platform technology to generate bispecific molecules with antibody-like properties called FIT-Ig® (Fabs-In-Tandem Immunoglobulin), designed to be more potent, less immunogenic and easier to manufacture. The company is also committed to diversifying its pipeline through selective licensing of its platform to partners worldwide.